Literature DB >> 20613515

Amyotrophic lateral sclerosis: current practice and future treatments.

Richard S Bedlack1.   

Abstract

PURPOSE OF REVIEW: Knowledge of amyotrophic lateral sclerosis, and in particular the care of patients with it, is evolving exponentially. More than 1700 articles with the phrase 'amyotrophic lateral sclerosis' have been published in the past 2 years; these form the basis for this timely review. RECENT
FINDINGS: In part 1, I give an update on the care of patients with amyotrophic lateral sclerosis, including ways to speed diagnosis, optimal use of riluzole, multidisciplinary teams, mechanical ventilation, gastrostomy tubes, lipid-lowering agents and symptom management. Although care has become more evidence-based, there remain a number of quandaries; for these, I will provide suggestions based upon my own experience. In part 2, I identify some exciting new treatment options that are under study. These include agents designed for novel targets within motor neurons and nonneuronal cells, agents designed for specific amyotrophic lateral sclerosis subtypes and interesting new technologies. Finally, in part 3, I define current barriers to developing even better therapeutics and offer ways around them.
SUMMARY: The care of patients with amyotrophic lateral sclerosis has evolved and is now more evidence-based than ever before. Exciting new therapies are currently being tested, which may revolutionize care even further. Barriers exist, but they are surmountable.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20613515     DOI: 10.1097/WCO.0b013e32833c7ac2

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  5 in total

Review 1.  Medical management of frontotemporal dementias: the importance of the caregiver in symptom assessment and guidance of treatment strategies.

Authors:  Gregory A Jicha
Journal:  J Mol Neurosci       Date:  2011-06-07       Impact factor: 3.444

2.  Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.

Authors:  Gregory A Jicha; Peter T Nelson
Journal:  Neurodegener Dis Manag       Date:  2011-04

3.  Associations between co-medications and survival in ALS-a cohort study from Austria.

Authors:  Hakan Cetin; Uros Klickovic; Jakob Rath; Gudrun Zulehner; Judith Füzi; Berthold Reichardt; Michael Hagmann; Julia Wanschitz; Wolfgang N Löscher; Eduard Auff; Fritz Zimprich
Journal:  J Neurol       Date:  2015-05-10       Impact factor: 4.849

4.  Delayed administration of VEGF rescues spinal motor neurons from death with a short effective time frame in excitotoxic experimental models in vivo.

Authors:  Luis B Tovar-y-Romo; Ricardo Tapia
Journal:  ASN Neuro       Date:  2012-03-27       Impact factor: 4.146

Review 5.  Trophic factors as modulators of motor neuron physiology and survival: implications for ALS therapy.

Authors:  Luis B Tovar-Y-Romo; Uri Nimrod Ramírez-Jarquín; Rafael Lazo-Gómez; Ricardo Tapia
Journal:  Front Cell Neurosci       Date:  2014-02-28       Impact factor: 5.505

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.